Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
565-02-009 ISMRM Abstract

Whole-tumor Histogram Analysis of Quantitative Synthetic MRI for Predicting PD-L1 Status in Nasopharyngeal Carcinoma

Primary: Neuro - Head & Neck/ENT
Secondary: Analysis Methods - Classification and Prediction
565-02-009 · Neuro-Oncology and Ear, Nose, and Throat Cancer · Wednesday, 13 May, 9:15 AM–10:10 AM · Digital Posters Row F
Keywords: Relaxometry T1 and T2 Magnetic Resonance Imaging (MRI) Nasopharyngeal carcinoma
Accepted
Yiheng Zhou 1, Jiankun Dai2, Bowen Zheng1, yu S qi1, Qingqing Wen2, Peng Wang1, Shudong Hu1
1Department of Radiology, Affiliated Hospital of Jiangnan University, Wuxi, China
2MR Research, Beijing, China
Presenting Author: Yiheng Zhou

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Chen YP, Chan A, Le QT, et al. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64-80. doi:10.1016/S0140-6736(19)30956-0. [doi]
2. Ma S, Zhou T, Huang Y, et al. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. Ann Transl Med. 2018;6(11):201. doi:10.21037/atm.2018.05.14. [doi]
3. Yang Y, Zhou T, Chen X, et al. Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study). J Immunother Cancer. 2021;9(12):e3790. doi:10.1136/jitc-2021-003790. [doi]
4. Ji S, Yang D, Lee J, et al. SyntheticMRI: Technologies and Applications in Neuroradiology. J Magn Reson Imaging. 2022;55(4):1013-25. doi:10.1002/jmri.27440. [doi]
5. Yang F, Li X, Li Y, et al. Histogram analysis of quantitative parameters from synthetic MRI: correlations with prognostic factors in nasopharyngeal carcinoma. Eur Radiol. 2023;33(8):5344-54. doi:10.1007/s00330-023-09553-9. [doi]
6. X Xiao Z, Tang Z, Zhang J, et al. Whole-tumor histogram analysis of monoexponential and advanced diffusion-weighted imaging for sinonasal malignant tumors. J Magn Reson Imaging. 2020;51(1):273-85. doi:10.1002/jmri.26857. [doi]
7. Yang F, Li Y, Lei H, et al. Histogram analysis of synthetic magnetic resonance imaging: Correlations with histopathological factors in head and neck squamous cell carcinoma. Eur J Radiol. 2023;160:110715. doi:10.1016/j.ejrad.2023.110715. [doi]
8. McSheehy PM, Weidensteiner C, Cannet C, et al. Quantified tumor t1 is a generic early-response imaging biomarker for chemotherapy reflecting cell viability. Clin Cancer Res. 2010;16(1):212-25.doi: 10.1158/1078-0432.CCR-09-0686. [doi]
9. Xue S, Hu M, Li P, et al. Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget 2017;8(30):49702-12. doi:10.18632/oncotarget.17922. [doi]
10. Zhong X, Li L, Yin J, et al. Reproducibility and usefulness of quantitative apparent diffusion coefficient measurements for predicting program death-ligand 1 expression in nasopharyngeal  carcinoma. Cancer Imaging 2023;23(1):98. doi:10.1186/s40644-023-00587-2. [doi]
11. Shen LF, Fu ZM, Zhou SH. The role of radiotherapy in tumor immunity and the potential of PET/CT in  detecting the expression of PD-1/PD-L1. Jpn J Radiol. 2024;42(4):347-53. doi:10.1007/s11604-023-01507-x. [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/565-02-009